Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Interest Expenses: 2010-2013

Historic Interest Expenses for Ani Pharmaceuticals (ANIP) over the last 4 years, with Dec 2013 value amounting to $98.

  • Ani Pharmaceuticals' Interest Expenses fell 99.89% to $98 in Q4 2013 from the same period last year, while for Dec 2013 it was $555,437, marking a year-over-year decrease of 30.07%. This contributed to the annual value of $467,000 for FY2013, which is 64.81% down from last year.
  • Ani Pharmaceuticals' Interest Expenses amounted to $98 in Q4 2013, which was down 99.97% from $374,476 recorded in Q2 2013.
  • In the past 5 years, Ani Pharmaceuticals' Interest Expenses ranged from a high of $501,002 in Q2 2012 and a low of $98 during Q4 2013.
  • Over the past 3 years, Ani Pharmaceuticals' median Interest Expenses value was $165,573 (recorded in 2011), while the average stood at $176,676.
  • In the last 5 years, Ani Pharmaceuticals' Interest Expenses spiked by 191.28% in 2012 and then crashed by 99.89% in 2013.
  • Ani Pharmaceuticals' Interest Expenses (Quarterly) stood at $172,000 in 2010, then declined by 3.74% to $165,573 in 2011, then tumbled by 46.93% to $87,863 in 2012, then crashed by 99.89% to $98 in 2013.
  • Its last three reported values are $98 in Q4 2013, $374,476 for Q2 2013, and $93,000 during Q1 2013.